Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlinkā„¢ technology, the first ADCs are addressing molecular targets for which they have already shown clinical promise.

Mablink is currently developing three ADC programs based on its proprietary linker, and exatecan (a topoisomerase I inhibitor) as the payload:

Discovery

Preclinical

Phase I

Phase II

Disc.

Precl.

Ph. I

Ph. II

MBK-103

Solid Tumors

Preclinical

MBK-102

Multiple Myeloma / Lymphomas

Preclinical

MBK-101

Acute Myeloid Leukemia

Preclinical